Citizens Jmp Forecasts Strong Price Appreciation for Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics (NASDAQ:ESPR) had its price objective upped by analysts at Citizens Jmp from $4.00 to $5.00 in a report issued on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s target price would indicate a potential upside of 104.92% from the stock’s current price.

A number of other equities research analysts have also issued reports on ESPR. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Piper Sandler began coverage on shares of Esperion Therapeutics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price on the stock. Needham & Company LLC raised their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Wall Street Zen downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.60.

Esperion Therapeutics Trading Down 1.2%

Shares of NASDAQ ESPR opened at $2.44 on Friday. The stock has a market cap of $626.62 million, a P/E ratio of -14.35, a PEG ratio of 1.17 and a beta of 1.11. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18. The business’s fifty day simple moving average is $3.28 and its 200-day simple moving average is $3.14.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million. On average, equities analysts forecast that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Transactions at Esperion Therapeutics

In other news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the completion of the transaction, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 15,543 shares of company stock worth $55,709. 1.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. DHJJ Financial Advisors Ltd. lifted its stake in Esperion Therapeutics by 209.2% during the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 6,380 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $35,000. KFG Wealth Management LLC purchased a new position in Esperion Therapeutics in the fourth quarter valued at approximately $37,000. Cary Street Partners Financial LLC acquired a new stake in Esperion Therapeutics during the fourth quarter worth approximately $38,000. Finally, Larson Financial Group LLC acquired a new stake in Esperion Therapeutics during the fourth quarter worth approximately $39,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.